Montero AJ, Escobar M, Lopes Prdvention, Glück S, Vogel C. Yu JP, Sun SP, Sun ZQ, Ni XC, Wang J, Li Y, et al. Spannuth, W.

Video

Top 10 Anti Cancer Foods (Part 1) - YOU NEED TO EAT THESE! For the best browsing experience please Anti-nagiogenesis JavaScript. Preventkon for Microsoft Edge and Precention Explorerother browsers. Anti angiogenic Protect your heart Anti-angiogenesis and cancer prevention treatments that stop tumours from growing preventipn own blood vessels. This might slow the growth of the cancer or sometimes shrink it. A cancer needs a good blood supply to provide itself with food and oxygen and to remove waste products. When it has reached 1 to 2 mm across, a tumour needs to grow its own blood vessels in order to continue to get bigger.

Anti-angiogenesis and cancer prevention -

Volunteer Volunteer Volunteer Home On-Site Volunteers Volunteer Endowment Patient Experience Teen Volunteer Leadership Program Children's Cancer Hospital Councils. Other Ways to Help Other Ways to Help Other Ways to Help Home Give Blood Shop MD Anderson Children's Art Project Donate Goods or Services Attend Events Cord Blood Bank.

Corporate Alliances Corporate Alliances Corporate Alliances Home Current Alliances. For Physicians. Refer a Patient Refer a Patient Refer a Patient Home Health Care Provider Resource Center Referring Provider Team Insurance Information International Referrals myMDAnderson for Physicians Second Opinion Pathology.

Clinical Trials Clinical Trials Clinical Trials Home. Departments, Labs and Institutes Departments, Labs and Institutes Departments, Labs and Institutes Home Departments and Divisions Labs Research Centers and Programs Institutes Specialized Programs of Research Excellence SPORE Grants.

Degree-Granting Schools Degree-Granting Schools Degree-Granting Schools Home School of Health Professions MD Anderson UTHealth Houston Graduate School. Research Training Research Training Research Training Home Early Career Pathway Programs Predoctoral Training Postdoctoral Training Mentored Faculty Programs Career Development.

Outreach Programs Outreach Programs Outreach Programs Home Project ECHO Observer Programs Comparative Effectiveness Training CERTaIN. Jump To:. Angiogenesis Inhibitors.

Possible side effects include: High blood pressure hypertension Wounds that are slow to heal Increased risk of internal bleeding Perforation of the intestine rare. We're here for you. Call us at or request an appointment online. Let's get started. Request an appointment online.

Help EndCancer. J Clin Oncol. Augustin HG. Translating angiogenesis research into the clinic: the challenges ahead. Br J Radiol. Holden SN, Eckhardt SG, Basser R, et al.

Clinical evaluation of ZD, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy.

Curr Mol Pharmacol. Chamberlain MC, Raizer J. Antiangiogenic therapy for high-grade gliomas. CNS Neurol Disord Drug Targets.

Higa G, Abraham J. Biological mechanisms of bevacizumab-associated adverse events. Expert Rev Anticancer Ther. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.

Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. Huang D, Ding Y, Li Y, et al. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Cancer Res. Votrient pazopanib package insert. Research Triangle Park, NC: GlaxoSmithKline; October Accessed May 15, Montemurro M, Schöffski P, Reichardt P, et al.

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer. Guirgis HM. A perspective on tyrosine kinase inhibitors in gastrointestinal stromal tumors and cancer: past and present with emphasis on future and cost.

Cancer Therapy. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs. Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non-small cell lung cancer: current and emerging options.

Hudes GR. Targeting mTOR in renal cell carcinoma. Board RE, Thatcher N, Lorigan P. Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?

Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

Curr Treat Options Oncol. Pharmacy Practice Affordable Medicines Biosimilars Compliance Compounding Drug Approvals. COVID Dermatology Diabetes Gastroenterology Hematology. mRNA Technology Neurology Oncology Ophthalmology Orthopedics. Featured Issue Featured Supplements.

COVID Resources. US Pharm. ABSTRACT: Angiogenesis is essential for tumor development and dissemination.

The investigation into the inhibition of tumor angiogenesis has shed new light on cancer treatment. With the approval of 14 molecularly targeted antiangiogenesis therapeutic drugs for cancer treatment, antiangiogenesis therapy represents one of the most significant advances in clinical oncology.

Since antiangiogenesis therapy is a targeted therapy aiming at angiogenic microvascular endothelial cells, fewer adverse effects and less drug resistance are associated with antiangiogenesis therapeutic drugs compared to chemotherapy agents. The combination of antiangiogenesis drugs with conventional chemotherapy significantly increases the response rate and quality of life of cancer patients.

However, more research is needed to fully understand the biological mechanisms of tumor angiogenesis and optimize this new treatment strategy.

To comment on this article, contact rdavidson uspharmacist. January In This Issue Digital Magazine Archives Subscription. Related CE. View More CE. Related Content.

Advertising Contacts Editorial Staff Professional Organizations Submitting a Manuscript Media Kit. About Us Contact Us Privacy Policy Do Not Sell My Personal Information Manage Preferences Careers Classifieds.

J Biol Chem. Tatum JL, Hoffman JM. Angiogenesis imaging methodology: AIM for clinical trials. Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, et al. Control of the immune response by pro-angiogenic factors. Sheu B-C, Chang W-C, Cheng C-Y, Lin H-H, Chang D-Y, Huang S-C.

Cytokine regulation networks in the cancer microenvironment. Front Biosci. Fahey E, Doyle SL. IL-1 family cytokine regulation of vascular permeability and angiogenesis. Front Immunol. Mountain DJ, Singh M, Menon B, Singh K. Am J Physiol Cell Physiol. Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, et al.

The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol. Huang Q, Duan I, Qian X, Fan J, Lv Z, Zhang X, et al. IL promotes angiogenic factors IL-6, IL-8, and Vegf production via Stat1 in lung adenocarcinoma.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. Yang Y, Sun M, Wang L, Jiao B. HIFs, angiogenesis, and cancer. J Cell Biochem. Niu Y, Bao L, Chen Y, Wang C, Luo M, Zhang B, et al.

HIF2-induced long noncoding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis. Chanmee T, Ontong P, Konno K, Itano N. Tumor-associated macrophages as major players in the tumor microenvironment.

Cancers Basel. Wang L, He T, Liu J, Tai J, Wang B, Chen Z, et al. Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment.

Exp Hematol Oncol. Tumor angiogenesis: therapeutic implications. McCormack PL, Keam SJ. Sandler A. Bevacizumab in non-small cell lung cancer.

Wu H-C, Huang C-T, Chang D-K. Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol. Mukherji S. Bevacizumab avastin. Am J Neuroradiol. Kelly RJ, Rixe O. Axitinib AG Small Mol Oncol. Article Google Scholar. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, et al.

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.

Houghton PJ. Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, et al. Everolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer.

J Clin Oncol. Chanzá NM, Xie W, Bilen MA, Dzimitrowicz H, Burkart J, Geynisman DM, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. PubMed Central Google Scholar. Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review.

J Clin Pharm Ther. Talati C, Sallman D, List A, editors. Lenalidomide: myelodysplastic syndromes with del 5q and beyond.

Seminars in hematology. Amsterdam: Elsevier; Cabanillas ME, Habra MA. Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat Rev.

Leonetti A, Leonardi F, Bersanelli M, Buti S. Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma. Ther Clin Risk Manag. Keisner SV, Shah SR.

Poole RM, Vaidya A. Ramucirumab: first global approval. Garon EB, Cao D, Alexandris E, John WJ, Yurasov S, Perol M. A randomized, double-blind, phase III study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non—small-cell lung cancer after disease progression after 1 previous platinum-based therapy REVEL : Treatment Rationale and Study Design.

Clin Lung Cancer. Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy.

Ther Adv Med Oncol. Syed YY. Ramucirumab: a review in hepatocellular carcinoma. Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment RESORCE : a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Profiles of drug substances, excipients and related methodology, vol. Le Tourneau C, Raymond E, Faivre S.

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors GIST. Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, et al. Thalidomide for treatment of multiple myeloma: 10 years later.

Blood J Am Soc Hematol. Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biol Targets Ther. Commander H, Whiteside G, Perry C. Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Cancer Cell. Grepin R, Guyot M, Jacquin M, Durivault J, Chamorey E, Sudaka A, et al. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.

J Clin Investig. Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol. Welti JC, Powles T, Foo S, Gourlaouen M, Preece N, Foster J, et al. Contrasting effects of sunitinib within in vivo models of metastasis.

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, et al. Resistance mechanisms to anti-angiogenic therapies in cancer.

Jiang B-H, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 HIF-1 and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Pereira ER, Frudd K, Awad W, Hendershot LM.

Endoplasmic reticulum ER stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 HIF-1 transcriptional activity on targets like vascular endothelial growth factor VEGF.

Luo D, Wang Z, Wu J, Jiang C, Wu J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. BioMed Res Int. Article PubMed PubMed Central Google Scholar.

Kitajima Y, Miyazaki K. The critical impact of HIF-1a on gastric cancer biology. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models.

Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. Hanahan D. Signaling vascular morphogenesis and maintenance. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res. Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects.

CA Cancer J Clin. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky T, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer. Qin S, Yi M, Jiao D, Li A, Wu K.

Distinct roles of VEGFA and ANGPT2 in lung adenocarcinoma and squamous cell carcinoma. J Cancer. Gyanchandani R, Alves MVO, Myers JN, Kim S. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.

Mol Cancer Res. Zhou Y, Wu C, Lu G, Hu Z, Chen Q, Du X. Okamoto S, Nitta M, Maruyama T, Sawada T, Komori T, Okada Y, et al. Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.

Brain Tumor Pathol. Schmidinger M. Third-line dovitinib in metastatic renal cell carcinoma. Welti J, Gourlaouen M, Powles T, Kudahetti S, Wilson P, Berney D, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, et al.

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, et al.

The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent. Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J.

Cancer immunotherapy resistance based on immune checkpoints inhibitors: targets, biomarkers, and remedies. Drug Resist Updates. Novel immune checkpoint targets: moving beyond PD-1 and CTLA Mol Cancer. Darvin P, Toor SM, Nair VS, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers.

Exp Mol Med. Reck M, Shankar G, Lee A, Coleman S, McCleland M, Papadimitrakopoulou VA, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.

Expert Rev Respir Med. Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J Sudbury, Mass. Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment.

Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 VEGFR 2 induces synergistic anti-tumour effect in vivo. Clin Exp Immunol.

Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, et al. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Wu FT, Xu P, Chow A, Man S, Krüger J, Khan KA, et al. Pre-and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro-or macro-metastatic disease.

Wang Q, Gao J, Di W, Wu X. Cancer Immunol Immunother. Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Rmili CW, Kiialainen A, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

Sci Transl Med. Article PubMed Google Scholar. Lacal PM, Atzori MG, Ruffini F, Scimeca M, Bonanno E, Cicconi R, et al. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.

Pharmacol Res. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

Nat Med. Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial. JAMA Oncol. Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, et al.

Am Soc Clin Oncol. Choueiri TK, Larkin JM, Oya M, Thistlethwaite FC, Martignoni M, Nathan PD, et al. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.

Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial REGONIVO, EPOC Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, et al.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate study. Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, et al. Nivolumab anti-PD-1; BMS, ONO in combination with sunitinib or pazopanib in patients pts with metastatic renal cell carcinoma mRCC.

Li J, Cong L, Liu J, Peng L, Wang J, Feng A, et al. The efficacy and safety of regorafenib in combination with anti-PD-1 antibody in refractory microsatellite stable metastatic colorectal cancer: a retrospective study.

Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial JVDF. Pardoll DM. Cancer vaccines. Finn OJ. Cancer vaccines: between the idea and the reality.

Nat Rev Immunol. Gatti-Mays ME, Redman JM, Collins JM, Bilusic M. Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother. Bose A, Lowe DB, Rao A, Storkus WJ. Melanoma Res. Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL.

Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models. Jha BK, Dong B, Nguyen CT, Polyakova I, Silverman RH. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.

Mol Ther. Lawson KA, Mostafa AA, Shi ZQ, Spurrell J, Chen W, Kawakami J, et al. Repurposing sunitinib with oncolytic reovirus as a novel immunotherapeutic strategy for renal cell carcinoma. Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, et al.

Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft. Int J Cancer. Tomita Y, Kurozumi K, Yoo JY, Fujii K, Ichikawa T, Matsumoto Y, et al. Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogates glioma invasion via the CCN1 and AKT signaling pathways.

Vo M-C, Nguyen-Pham T-N, Lee H-J, Lakshmi TJ, Yang S, Jung S-H, et al. Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model.

Lapenta C, Donati S, Spadaro F, Lattanzi L, Urbani F, Macchia I, et al. Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine. Nguyen-Pham T-N, Jung S-H, Vo M-C, Thanh-Tran H-T, Lee Y-K, Lee H-J, et al.

Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma. J Immunother. Sakamaki I, Kwak LW, Cha S, Yi Q, Lerman B, Chen J, et al. Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas.

Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells provenge plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

Cancer Interdiscip Int J Am Cancer Soc. Boydell E, Marinari E, Migliorini D, Dietrich P-Y, Patrikidou A, Dutoit V. Bota DA, Chung J, Dandekar M, Carrillo JA, Kong X-T, Fu BD, et al. CNS Oncol. Nooka AK, Wang ML, Yee AJ, Kaufman JL, Bae J, Peterkin D, et al. Assessment of safety and immunogenicity of PVX vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial.

Tilgase A, Olmane E, Nazarovs J, Brokāne L, Erdmanis R, Rasa A, et al. Multimodality treatment of a colorectal cancer stage IV patient with FOLFOX-4, bevacizumab, Rigvir oncolytic virus, and surgery. Case Rep Gastroenterol. Kato D, Yaguchi T, Iwata T, Morii K, Nakagawa T, Nishimura R, et al.

Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.

Jpn J Clin Immunol. Feros DL, Lane L, Ciarrochi J, Blackledge JT. Acceptance and Commitment Therapy ACT for improving the lives of cancer patients: a preliminary study. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.

Shi S, Wang R, Chen Y, Song H, Chen L, Huang G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.

PLoS ONE. Bocca P, Di Carlo E, Caruana I, Emionite L, Cilli M, De Angelis B, et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model.

Zhang Q, Zhang H, Ding J, Liu H, Li H, Li H, et al. Combination therapy with EpCAM-CAR-NK cells and regorafenib against human colorectal cancer models. J Immunol Res. Lennernäs B, Albertsson P, Lennernäs H, Norrby K. Chemotherapy and antiangiogenesis. Acta Oncol. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Oliva P, Decio A, Castiglioni V, Bassi A, Pesenti E, Cesca M, et al. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.

Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP in combination with cisplatin. Jpn J Cancer Res.

Devineni D, Klein-Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP Kong C, Zhu Y, Sun C, Li Z, Sun Z, Zhang X, et al.

Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Bow H, Hwang LS, Schildhaus N, Xing J, Murray L, Salditch Q, et al. Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.

J Neurosurg. Thomas AL, Trarbach T, Bartel C, Laurent D, Henry A, Poethig M, et al. Ann Oncol. Cooney MM, Tserng K-Y, Makar V, McPeak RJ, Ingalls ST, Dowlati A, et al. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU and paclitaxel in recurrent or metastatic carcinoma of the head and neck.

Cancer Chemother Pharmacol. Okamoto I, Yoshioka H, Takeda K, Satouchi M, Yamamoto N, Seto T, et al. Phase I clinical study of the angiogenesis inhibitor TSU combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer.

J Thorac Oncol. Gietema J, Hoekstra R, de Vos F, Uges D, van der Gaast A, Groen H, et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondinmimetic angiogenesis inhibitor ABT with gemcitabine and cisplatin in patients with solid tumors.

Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, et al. Safety and pharmacokinetic effects of TNP, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non—small-cell lung cancer.

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, et al.

Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Morganti AG, Cellini F, Mignogna S, Padula GD, Caravatta L, Deodato F, et al. Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.

Future Oncol. Koukourakis MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, et al.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.

Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, et al. Bondarenko IM, Ingrosso A, Bycott P, Kim S, Cebotaru CL. Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. BMC Cancer. Chau I, Fakih M, García-Alfonso P, Linke Z, Ruiz Casado A, Marques EP, et al.

Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, et al. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Wrona A, Dziadziuszko R, Jassem J. Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents.

Transl Lung Cancer Res. Overgaard J. Hypoxic radiosensitization: adored and ignored. Gray LH, Conger AD, Ebert M, Hornsey S, Scott O. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy.

Br J Radiol. Amano M, Suzuki M, Andoh S, Monzen H, Terai K, Williams B, et al. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol. Shintani S, Li C, Mihara M, Klosek SK, Terakado N, Hino S, et al. Anti-tumor effect of radiation response by combined treatment with angiogenesis inhibitor, TNP, in oral squamous cell carcinoma.

Oral Oncol.

Thank you for visiting nature. You are using Anti-angiogenesis and cancer prevention browser version with limited support for CSS. To obtain preventioon best experience, we recommend you use a Anti-nagiogenesis up to date browser Anti-angoogenesis turn off Anti-angiogenesis and cancer prevention preventioon in Internet Fuel Consumption Control. In Metabolic health benefits meantime, to Anti-angiogenesos continued support, we are displaying the site without styles and JavaScript. Angiogenesis, the formation of new blood vessels, is a complex and dynamic process regulated by various pro- and anti-angiogenic molecules, which plays a crucial role in tumor growth, invasion, and metastasis. With the advances in molecular and cellular biology, various biomolecules such as growth factors, chemokines, and adhesion factors involved in tumor angiogenesis has gradually been elucidated. Targeted therapeutic research based on these molecules has driven anti-angiogenic treatment to become a promising strategy in anti-tumor therapy.